All In Biotech

Drug Trial Radar · NCT07834398

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Nov 14, 2025

Primary completion

Apr 13, 2026

Study completion Apr 21, 2026

Sponsor

Lead sponsor
Zagazig UniversityGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Najran University
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults. 150 participants with BMI \>30 will be randomized into three groups and followed for 6 months to assess changes in weight, BMI, lipid profile, and liver functions.

Conditions

  • Non-diabetec Obesity
  • Obesity (Disorder)

Interventions

  • DulaglutideDrug

    weight control drug dulaglutide 1.5 mg subcutaneous injection GLP-1 receptor agonist

  • SemagludtideDrug

    Weight control drug semaglutide 2.4 mg subcutanous injection GLP-1 receptor agonist

  • TirzepatideDrug

    Weight control drug tirzepatide 15 mg subcutanous injection GLP-1 receptor agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in body weight at 3 and 6 monthsTime frame: Baseline, Week 12 (3 months) and Week 24 (6 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Najran General Hospital

    Najran, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.